124 related articles for article (PubMed ID: 38507992)
21. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
22. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
23. Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer.
Graboyes EM; Garrett-Mayer E; Ellis MA; Sharma AK; Wahlquist AE; Lentsch EJ; Nussenbaum B; Day TA
Cancer; 2017 Dec; 123(24):4841-4850. PubMed ID: 28841234
[TBL] [Abstract][Full Text] [Related]
24. Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.
Pitakpaiboonkul P; Jiarpinitnun C; Pattaranutaporn P; Ngamphaiboon N
Cancer Med; 2024 Feb; 13(4):e7047. PubMed ID: 38457195
[TBL] [Abstract][Full Text] [Related]
25. Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).
Pectasides E; Rampias T; Sasaki C; Perisanidis C; Kouloulias V; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A
PLoS One; 2014; 9(4):e94273. PubMed ID: 24722213
[TBL] [Abstract][Full Text] [Related]
26. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
28. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
29. Low albumin-to-alkaline phosphatase ratio is associated with inferior prognosis in patients with head and neck cancer underwent concurrent chemoradiation: A propensity score-matched analysis.
Kim D; Ki Y; Kim W; Park D; Joo J; Jeon H; Nam J
J Cancer Res Ther; 2023; 19(5):1340-1344. PubMed ID: 37787305
[TBL] [Abstract][Full Text] [Related]
30. Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials.
Yalamanchali A; Yang K; Roof L; Lopetegui-Lia N; Schwartzman LM; Campbell SR; Woody NM; Silver N; Koyfman S; Geiger JL; Yilmaz E
Head Neck; 2023 Apr; 45(4):862-871. PubMed ID: 36806299
[TBL] [Abstract][Full Text] [Related]
31. Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab.
Haas M; Lein A; Fuereder T; Schnoell J; Brkic FF; Campion NJ; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Int Immunopharmacol; 2023 Oct; 123():110799. PubMed ID: 37598631
[TBL] [Abstract][Full Text] [Related]
32. The influence of antibiotic administration on the outcomes of head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiation.
Rühle A; Zou J; Glaser M; Halle L; Gkika E; Schäfer H; Knopf A; Becker C; Grosu AL; Popp I; Nicolay NH
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2605-2616. PubMed ID: 36764957
[TBL] [Abstract][Full Text] [Related]
33. Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer.
Philips R; Alnemri A; Amin D; Patel J; Topf MC; Johnson JM; BarAd V; Axelrod R; Argiris A; Fundakowski C; Luginbuhl AJ; Cognetti DM; Curry JM
Cancer; 2024 Mar; 130(6):863-875. PubMed ID: 37788128
[TBL] [Abstract][Full Text] [Related]
34. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS
Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.
Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Di Stefano J; Knepley C; Limaye S; Mamtani R; Wisnivesky J; Damjanov N; Langer CJ; Cohen RB; Sigel K
Cancer; 2019 Feb; 125(3):406-415. PubMed ID: 30341983
[TBL] [Abstract][Full Text] [Related]
36. Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: An analysis from an endemic tertiary center.
Lai CL; Lin CH; Su YC; Shih YH; Wang CC; Teng CJ; Chou CW
Cancer Med; 2023 Mar; 12(6):6802-6810. PubMed ID: 36426417
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
38. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.
Pestana RC; Becnel M; Rubin ML; Torman DK; Crespo J; Phan J; Hanna E; Bell D; Glisson BS; Johnson JM; Lee JJ; Ferrarotto R
Oral Oncol; 2020 Feb; 101():104523. PubMed ID: 31864957
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy for head and neck squamous cell carcinoma].
Chen J; Chen M; Wu HT
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181
[TBL] [Abstract][Full Text] [Related]
40. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
